Longevity Escape Velocity 2025: The Current State of Anti-Aging Science

Here's the late-2025 snapshot—what's real, what's hype, and where #LEV (Longevity Escape Velocity) currently stands on the "slow → reverse → pause" continuum.

(All citations are from papers or trial registers published in the last 120 days.)

---

1. SLOW aging – what's already deployable

---

Semaglutide (yes, the diabetes drug)

• New 32-week RCT in adults with HIV-lipodystrophy (n = 84) shows -3.1 y average epigenetic-age deceleration on the PCGrimAge clock, multi-organ benefit (brain, vasculature, inflammation).

• Dose used: 1 mg/week—identical to the diabetes script your doctor can write today. PMID 40791720 (July '25)

Hyper-baric oxygen (HBOT)

• 64-plussers got 60 sessions, 3 months. Telomere lengthening ≈ 20%, senescent cells ↓ 37%. Cheap, safe, already reimbursable for wound care in most countries. Aging-US, Aug '25.

Therapeutic plasma exchange (TPE)

• RCT across bi-weekly or monthly rounds in 42 healthy ≥ 50 y. 15 epigenetic clocks all roll back (mean –4 y). Best combo: TPE + IVIG. PubMed 40424097 (July '25)

Translation: If your only goal is to slow the ticking right now, a cocktail of metformin, semaglutide, intermittent HBOT and twice-yearly plasma exchange has more published human data (2025) than 90% of "longevity supplements".

---

2. REVERSE aging in humans – first foot in the door

---

Partial epigenetic reprogramming with OSK (Oct4-Sox2-Klf4, minus c-Myc to avoid teratomas)

a) Life Biosciences ER-100

• Non-human-primate NAION model: 44-week course restored retinal-ganglion-cell methylation patterns and axonal firing (pattern-ERG). IND-enabling tox done; FDA pre-IND feedback positive.

• First human trials open Q1-2026 for glaucoma & NAION (two intravitreal injections). ARDD Copenhagen, Aug '25

b) YouthBio YB-002

• Brain-specific AAV-OSK construct; FDA "INTERACT" meeting complete → green-lighted path to Phase I in Alzheimer's patients. Expect first-in-man 2026. PR Newswire 09-Oct-25

c) Safety precedent

• Single-blind TPE + IVIG data (above) shows no severe adverse events in 6-month follow up—plausible regulatory template for how "rejuvenation" can be sold to FDA without a cancer scare.

---

3. PAUSE aging indefinitely – the LEV metric

---

Definition: increase in remaining life-expectancy > 1 calendar year per 1 calendar year of research.

Mouse data (LEV-Foundation multi-drug study closed late '24)

• Best combo (rapa + senolytics + telomerase gene-therapy + young stem cells): median lifespan +4 months in 18-month-old mice (≈ +8%). Needed: +12 months to hit Aubrey de Grey's "prove-it" bar. No cigar.

• Expect combo-tweak version 2.0 read-out Q3-2026. CEO Today Mag, Aug '25

Human translation

Most insiders' 2025 probability grid (Kurzweil, de Grey, Church) converges on 50% chance of LEV between 2029-2035, PROVIDED:

1. ≥12-month mouse extension achieved within 3 years

2. AI-accelerated biomarker validation (FDA GRAIL, Altos "cell-age" panel)

3. At least one jurisdiction treats "biological aging" as an indication rather than a risk factor—currently under pilot at UK MHRA and Singapore HSA.

---

Bottom line

• Today you can already "slow" biological age 3–5 years with physician-accessible tools.

• First approved "reversal" interventions (eye, brain, liver) enter clinics 2026-27.

• True pause/LEV still rides on a big mouse milestone not yet met → watch the 2026 combo-mouse data drop.

The Path Forward

The convergence of epigenetic reprogramming, plasma exchange protocols, and metabolic interventions represents the first practical toolkit for human age deceleration. While true longevity escape velocity remains on the horizon, the 2025 data demonstrates we're transitioning from theoretical frameworks to deployable interventions with measurable biomarker improvements.